Skip to content

Jean Kim

2 papers in the library · 34 citations · publishing 2019

Papers

Effects of subanesthetic intravenous ketamine infusion on neuroplasticity-related proteins in the prefrontal cortex, amygdala, and hippocampus of Sprague-Dawley rats

IBRO Reports January 16, 2019 Michael Zhang, Kennett D. Radford, Mercedes Y. Driscoll et al. 34 citations

A single intravenous infusion of ketamine in rats produces dose-dependent and brain region-specific changes in proteins linked to neural plasticity. A high dose (40 mg/kg) increased c-Fos in the medial prefrontal cortex and amygdala, and increased pERK in the medial prefrontal cortex and hippocampus. A low dose (10 mg/kg) increased BDNF in the amygdala but decreased pERK in the medial prefrontal cortex and hippocampus. These results suggest that the route and dose of ketamine administration matter for its effects on neuroplasticity-related proteins.

Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.

New England Journal of Medicine May 22, 2019 Jean Kim, Tiffany R. Farchione, Andrew Potter et al.

The FDA has approved esketamine as a new antidepressant for treatment-resistant depression. The drug offers a rapid onset of action, a key advantage for patients who have not responded to other treatments. The approval followed an evaluation of the drug's benefits and risks by the agency.